One of the novel synthesis’s key features is a bioinspired photooxygenation-allylic hydroperoxide rearrangement sequence that makes it easier to add functional groups in the synthesis’s final stages.
Researchers at Scripps Research have recently discovered that when taken with checkpoint inhibitors, the immunosuppressive medication ruxolitinib, which is licenced, enhanced T-cell responses and increased the drugs’ ability to fight cancer.
The researchers discovered that a statin called pitavastatin efficiently decreases IL-33 expression by preventing the activation of the TBK1-IRF3 signalling pathway.
When the medication was given to mice whose tumors had been surgically removed, similar results were also shown.
To increase the efficacy of treatment, scientists from Virginia Tech’s College of Engineering have created a novel cancer immunotherapy that targets cancer-killing cytokines where they are found in tumours.
A recent study sheds light on why leukaemic stem cells that were spared from chemotherapy go on to proliferate and develop into AML cells after treatment.
Researchers identified an allergy pathway, which can produce antitumor immunity.
Intratumoral therapy, in which cancer drugs are injected directly into tumors
Washington State University has developed a new technology for the development of cells using a bioreactor for cancer therapy. this technique develops cancer-detecting white blood cells (WBC) which supports immunotherapy.
Researchers at Washington State University have created a bioreactor the size of a minifridge that can produce T cells at 95% of their maximal development rate, which is around 30% quicker than what is possible with existing technology. They developed it using T cells from cattle. They expect it will function similarly on human cells.
A recent research study led by Karin Schelch and Michael Grusch from MedUni Vienna identified the oncoprotein YB-1 as an attractive therapeutic target in PM and demonstrates that indirect targeting of YB-1 is a promising approach to enhance sensitivity to chemo- and radiotherapy.
